The EUROASPIRE Surveys: Lessons Learned in Cardiovascular Disease Prevention

Overview

Journal Cardiovasc Diagn Ther

Publisher AME Publishing Company

Specialty Cardiology & Vascular Diseases

Date 2018 Jan 6

PMID 29302468

Citations 22

Authors

Kornelia Kotseva

Affiliations

Soon will be listed here.

Abstract

The Joint European Societies (JES) guidelines on cardiovascular disease (CVD) prevention published in 1994, 1998, 2003, 2007, 2012 and 2016 defined lifestyle and risk factors targets for patients with coronary or other atherosclerotic disease and people at high risk of developing CVD. Guideline implementation in Europe has been evaluated with four cross-sectional EUROASPIRE surveys starting in mid-1990s. The results showed poor lifestyle and risk factor management in patients with CHD and in high CVD risk people with high prevalences of smoking, obesity, central obesity and diabetes. The control of blood pressure, lipids and glucose was far from optimal. A comparison across the recent three surveys provided a unique description of time trends for secondary prevention over a period of 14 years. The results showed adverse lifestyle trends, a substantial increase in obesity, central obesity and diabetes. Despite significant improvement of blood pressure and lipid control many patients were not reaching the risk factor goals and there was no change in glucose control. Comparing the most recent two surveys, there were no major differences in lifestyle and risk factor management in people at high risk of developing CVD. A new approach to CVD prevention integrating primary and secondary prevention into a modern preventive cardiology programme, focusing on lifestyle and risk factor management is required, in order to reduce the risk of CVD events and improve quality of life in patients with CHD and those at high risk of developing CVD.

Citing Articles

The journey of the cardiovascular polypill from its conception to the WHO List of Essential Medicines.

Fuster V, Sanz G, Castellano J Nat Cardiovasc Res. 2025; .

PMID: 40069526 DOI: 10.1038/s44161-025-00619-z.

Prescriptive Appropriateness and Efficacy of Cholesterol-Lowering Drugs in a Secondary Prevention Setting-A Retrospective Analysis from Two Italian Cardiac Rehabilitation Centers.

Saladini F, Baggio S, Marcato F, Campisi F, Verlato R, Pasquetto G J Clin Med. 2025; 13(24.

PMID: 39768428 PMC: 11677457. DOI: 10.3390/jcm13247505.

El Ayech Boudiche F, Boudiche S, Othmani S, Mehri H, Larbi M, Yaakoub A Tunis Med. 2024; 102(3):151-156.

PMID: 38545710 PMC: 11358825. DOI: 10.62438/tunismed.v102i3.4713.

Evolocumab-Based LDL-C Management in High and Very High Cardiovascular Risk Patients in German Clinical Practice: The HEYMANS Study.

Lehrke M, Vogt A, Schettler V, Girndt M, Fraass U, Tabbert-Zitzler A Adv Ther. 2024; 41(3):1184-1200.

PMID: 38286961 PMC: 10879337. DOI: 10.1007/s12325-023-02757-x.

The Benefits of a Comprehensive Cardiac Rehabilitation Program for Patients with Acute Coronary Syndrome: A Follow-Up Study.

Craciun L, Buleu F, Pah A, Badalica-Petrescu M, Bodea O, Man D J Pers Med. 2023; 13(10).

PMID: 37888127 PMC: 10608079. DOI: 10.3390/jpm13101516.

References

De Backer G, De Bacquer D, Ryden L, Kotseva K, Gaita D, Georgiev B . Lifestyle and risk factor management in people at high cardiovascular risk from Bulgaria, Croatia, Poland, Romania and the United Kingdom who participated in both the EUROASPIRE III and IV primary care surveys. Eur J Prev Cardiol. 2016; 23(15):1618-27. DOI: 10.1177/2047487316645474. View

Piepoli M, Hoes A, Agewall S, Albus C, Brotons C, Catapano A . 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by.... Eur Heart J. 2016; 37(29):2315-2381. PMC: 4986030. DOI: 10.1093/eurheartj/ehw106. View

Kotseva K, Wood D, De Backer G, De Bacquer D, Pyorala K, Keil U . EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil. 2009; 16(2):121-37. DOI: 10.1097/HJR.0b013e3283294b1d. View

Kotseva K, Ryden L, De Backer G, De Bacquer D, Wood D . EURObservational research programme: EUROASPIRE. Eur Heart J. 2015; 36(16):950-1. DOI: 10.1093/eurheartj/ehv047. View

Kotseva K, De Bacquer D, Jennings C, Gyberg V, De Backer G, Ryden L . Time Trends in Lifestyle, Risk Factor Control, and Use of Evidence-Based Medications in Patients With Coronary Heart Disease in Europe: Results From 3 EUROASPIRE Surveys, 1999-2013. Glob Heart. 2016; 12(4):315-322.e3. DOI: 10.1016/j.gheart.2015.11.003. View

Kotseva K, Wood D, De Backer G, De Bacquer D, Pyorala K, Reiner Z . EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries. Eur J Cardiovasc Prev Rehabil. 2010; 17(5):530-40. DOI: 10.1097/HJR.0b013e3283383f30. View

. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J. 1998; 19(10):1434-503. DOI: 10.1053/euhj.1998.1243. View

De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J . European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by.... Eur J Cardiovasc Prev Rehabil. 2003; 10(4):S1-S10. DOI: 10.1097/01.hjr.0000087913.96265.e2. View

. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet. 2001; 357(9261):995-1001. DOI: 10.1016/s0140-6736(00)04235-5. View

10.

Clark A, Hartling L, Vandermeer B, McAlister F . Meta-analysis: secondary prevention programs for patients with coronary artery disease. Ann Intern Med. 2005; 143(9):659-72. DOI: 10.7326/0003-4819-143-9-200511010-00010. View

11.

Wood D, Kotseva K, Connolly S, Jennings C, Mead A, Jones J . Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised.... Lancet. 2008; 371(9629):1999-2012. DOI: 10.1016/S0140-6736(08)60868-5. View

12.

Younus A, Aneni E, Spatz E, Osondu C, Shaharyar S, Roberson L . Prevalence of Ideal Cardiovascular Health Among Adults in the United States. J Am Coll Cardiol. 2015; 66(14):1633-1634. DOI: 10.1016/j.jacc.2015.06.1348. View

13.

. EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events. Eur Heart J. 1997; 18(10):1569-82. DOI: 10.1093/oxfordjournals.eurheartj.a015136. View

14.

Taylor R, Brown A, Ebrahim S, Jolliffe J, Noorani H, Rees K . Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. Am J Med. 2004; 116(10):682-92. DOI: 10.1016/j.amjmed.2004.01.009. View

15.

De Smedt D, Kotseva K, De Bacquer D, Wood D, De Backer G, Dallongeville J . Cost-effectiveness of optimizing prevention in patients with coronary heart disease: the EUROASPIRE III health economics project. Eur Heart J. 2012; 33(22):2865-72. DOI: 10.1093/eurheartj/ehs210. View

16.

Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M . European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted.... Eur Heart J. 2012; 33(13):1635-701. DOI: 10.1093/eurheartj/ehs092. View

17.

Bartnik M, Ryden L, Ferrari R, Malmberg K, Pyorala K, Simoons M . The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J. 2004; 25(21):1880-90. DOI: 10.1016/j.ehj.2004.07.027. View

18.

Kotseva K, Wood D, De Backer G, De Bacquer D, Pyorala K, Keil U . Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet. 2009; 373(9667):929-40. DOI: 10.1016/S0140-6736(09)60330-5. View

19.

Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R . European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by.... Eur J Cardiovasc Prev Rehabil. 2007; 14 Suppl 2:S1-113. DOI: 10.1097/01.hjr.0000277983.23934.c9. View

20.

Kotseva K, Wood D, De Bacquer D, De Backer G, Ryden L, Jennings C . EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol. 2015; 23(6):636-48. DOI: 10.1177/2047487315569401. View